Regulatory requirements for Biotechnological Products Part I

An overview of the regulatory information required for a clinical trial /marketing authorisation application using a theoretical biotechnological protein product: A Pegylated Monoclonal Antibody.

Previous
Previous

Regulatory Requirements for Biotechnological Products - Good Tissue Practice

Next
Next

A study of manufacture monoclonal antibodies Part IV